Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL10030513 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL18402620 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| EP-4232012-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | Massachusetts Institute of Technology (US) | 2023-08-30 | — | — | EP | claimed |
| EP-3999641-A2 | METHODS AND COMPOSITIONS FOR GENE SPECIFIC DEMETHYLATION AND ACTIVATION | National University of Singapore (SG) | 2022-05-25 | — | — | EP | claimed |
| WO-2022087526-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-28 | — | — | WO | claimed |
| CN-114402071-A | Methods and compositions for gene-specific demethylation and activation | 新加坡国立大学 | 2022-04-26 | — | — | CN | claimed |
| US-11197881-B2 | HDAC inhibitor compositions for reactivation of the X chromosome | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-12-14 | — | — | US | claimed |
| CN-108290920-B | 5 '-dibenzyl phosphate of 5-azacytidine or 2' -deoxy-5-azacytidine | 大原药品工业株式会社 | 2021-08-10 | — | — | CN | claimed |
| US-20210155928-A1 | RNA-AIDED IMMUNOTHERAPEUTICS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2021-05-27 | — | — | US | claimed |
| US-20210128600-A1 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-05-06 | — | — | US | claimed |
| EP-3801562-A1 | RNA-AIDED IMMUNOTHERAPEUTICS | Beth Israel Deaconess Medical Center (US) | 2021-04-14 | — | — | EP | claimed |
| EP-1332756-A2 | Compositions and methods for restoring a normal pattern of imprinting to cells | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020197639-A1 | Methods and products for analyzing nucleic acids based on methylation status | U.S. GENOMICS, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002101353-A2 | METHODS AND PRODUCTS FOR ANALYZING NUCLEIC ACIDS BASED ON METHYLATION STATUS | U.S. GENOMICS, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1224303-A2 | TMS1 COMPOSITIONS AND METHODS OF USE | Emory University (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1218036-A1 | CELL BASED ASSAY | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| EP-1176864-A2 | CHEMICAL AND PHYSICAL TREATMENT THAT STIMULATE RECOMBINATION | The University of Chicago (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2001029235-A2 | TMS1 COMPOSITIONS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001021215-A1 | CELL BASED ASSAY | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2000054574-A2 | CHEMICAL AND PHYSICAL TREATMENT THAT STIMULATE RECOMBINATION | THE UNIVERSITY OF CHICAGO (US) | 2000-09-21 | — | — | WO | claimed |
| US-5856090-A | LINKAGE BETWEEN A NUCLEIC ACID SEGMENT AND A POLYPEPTIDE DETERMINANT ENCODED BY THE NUCLEIC ACID SEGMENT AND A POLYPEPTIDE DETERMINANT | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-01-05 | — | — | US | claimed |